UriPath™ & UriPath-STI™

UriPath™ & UriPath-STI™

The bacteria from a UTI can spread from the bladder to one or both kidneys reducing kidney function and even causing renal failure. In the elderly population, untreated UTIs are one of the leading causes of morbidity.

UriPath™ (Multiplex Urinary RT-PCR Pathogen Panel Testing)

The combination of inefficient diagnostics and a plethora of different UTI symptoms have caused many UTIs to be misdiagnosed.

Standard urine culture tests take on average 3-7 days and are not able to grow many of the pathogens that cause UTIs. With long wait times and no certainty of a diagnosis, physicians have commonly turned to prescribing broad-spectrum antibiotics in hopes of treating the patient’s urinary tract infection.

Unfortunately, the overuse of these broad-spectrum antibiotics for a variety of illnesses has caused many of the causative pathogens to develop resistance to certain antibiotics, rendering those antibiotics ineffective in treatment. These issues are why we have worked hard to develop our UriPath™ test.

Not only do STIs need to be treated to help relieve painful symptoms, but they can cause other health complications such as pelvic inflammatory disease, infertility, heart disease, and cancer to name a few.

UriPath-STI™ (Multiplex Urinary STI RT-PCR Pathogen Panel Testing)

STIs (sexually transmitted infections) have commonly been tested for through the collection of blood or urine samples with results taking 5-10 days to be reported on average. Due to the progression of multi-drug resistant organisms, STI-related complications, and ease of transmission, a quick diagnosis, and accurate treatment are critically important in treating the patient and this hidden epidemic.

Our RT-PCR UriPath™ & UriPath-STI™ panels are critical in saving time in the diagnosis and treatment processes. As several pathogens from our large molecular diagnostic testing menu are tested all at once, specimen samples are resulted 6-8 hours from when our lab receives the specimen and the identification of antibiotic resistance genes allows physicians to practice precision medicine by giving the relevant data needed for prescribing the correct medication for that specific infection.

Clinical Relevance & Advantages

  • Prevents delays in diagnosis and treatment (6-8 hrs from lab arrival)
  • Tests for bacterial, fungal, and viral pathogens
  • Reduces the spread of infection
  • Detects polymicrobial infections simultaneously
  • Identifies antibiotic-resistant genes
  • Allows for precision medicine through narrow-spectrum antibiotics
  • Limits unnecessary exposure to broad-spectrum antibiotics
  • Unaffected by the use of current medications such as antibiotics
  • Cost savings from earlier diagnosis

UriPath™ panel tests a patient’s urine for a total of 19 pathogens, including:

Fungi: 1. Candida albicans, 2. Candida glabrata, 3. Candida parapsilosis, 4. Candida tropicalis

Bacteria: 1. Acinetobacter baumannii, 2. Citrobacter freundii, 3. Enterobacter aerogenes, 4. Enterobacter cloacae, 5. Enterococcus faecalis, 6. Enterococcus faecium, 7. Escherichia coli, 8. Klebsiella pneumoniae, 9. Morganella morganii, 10. Proteus mirablis, 11. Proteus vulgaris, 12. Pseudomonas aeruginosa, 13. Staphylococcus aureus, 14. Staphylococcus saprophyticus & 15. Streptococcus agalactiae

ResistantPath: 1. mecA, 2. mcr-1, 3. tetM, 4. tetS, 5. vanA, 6. vanB & 7. sul1

UriPath-STI™ tests a patient’s swab of urine for a total of 12 sexually transmitted infection-causing pathogens, including:

Virus: 1. Human Papilloma Virus strain 16, 2. Human Papilloma Virus strain 18

Bacteria: 1. Atopobium vagniae, 2. Chlamydia trachomatis, 3. Gardnerella vaginalis, 4. Mycoplasma hominis, 5. Mycoplasma genitalium, 6. Neisseria gonorrhoeae, 7. Trichomonas vaginalis, 8. Ureaplasma parvum, 9. Ureaplasma urealyticum, 10. CT/NG (Chlamydia trachomatis & Neisseria gonorrhoeae)

ResistantPath: 1. mecA, 2. mcr-1, 3. tetM, 4. tetS, 5. vanA, 6. vanB & 7. sul1

Certifications and Accreditations